Want to see AU:OCC full AI Analyst Report?

Orthocell Ltd (OCC) Price & Analysis

79 Followers

OCC Stock Chart & Stats

AU$0.78

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.78

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.60 - AU$1.30

Previous CloseN/A

Volume80.90K

Average Volume (3M)358.99K

Market Cap

AU$177.06M

Enterprise ValueAU$154.78M

Total Cash (Recent Filing)AU$44.15M

Total Debt (Recent Filing)AU$1.55M

Price to Earnings (P/E)―

Beta1.50

Next Earnings

Feb 19, 2027

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding272,393,700

10 Day Avg. Volume422,739

30 Day Avg. Volume358,989

Financial Highlights & Ratios

PEG Ratio-0.37

Price to Book (P/B)5.55

Price to Sales (P/S)16.74

P/FCF Ratio-13.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$1.13

Price Target Upside44.87% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.04

Revenue Forecast (FY)AU$19.60M

Bulls Say, Bears Say

Bulls Say

Strong Revenue ScalingRapid multi-year revenue expansion indicates growing commercial traction for Orthocell’s regenerative medicine products. Continued top-line scaling can broaden the installed customer base, support operating investment, and create a foundation for eventual operating leverage if costs grow more slowly than sales.

Conservative LeverageVery low leverage limits financial risk while Orthocell continues investing in product development, regulatory approvals and commercial expansion. A lightly indebted balance sheet provides greater flexibility than a highly leveraged structure if the company needs to fund growth or absorb continued losses.

Commercial Product PortfolioOrthocell combines commercialised regenerative medicine products with additional development programs, creating a platform rather than reliance on a single therapy. Remplir and Striate+ provide existing commercial channels, while OrthoATI offers potential longer-term expansion within regenerative medicine.

Bears Say

Persistent UnprofitabilityThe scale of current losses shows that revenue growth has not yet translated into a sustainable earnings model. Persistent negative margins can limit internally funded investment, require continued external capital, and make future profitability dependent on substantial improvement in operating leverage.

Ongoing Cash BurnMaterially negative operating and free cash flow means the business is not currently self-funding its operations and investment program. If cash conversion remains weak, Orthocell may face increasing funding needs, reducing financial flexibility even though its balance sheet carries limited debt.

Margin CompressionThe sharp decline in gross margin raises concern about the durability and economics of recent revenue growth. Lower gross profit per unit leaves less capacity to absorb research, commercial and administrative costs, making the path to breakeven more dependent on margin recovery as well as further sales expansion.

Orthocell Ltd News

Orthocell outlines terms and limitations of Q1 FY27 investor webinar

Orthocell Ltd ( ($AU:OCC) ) has issued an announcement. Orthocell Ltd has released a Q1 FY27 investor webinar...

9h ago

OCC

Orthocell boosts Remplir-driven revenue as U.S. rollout and Asian expansion gain pace

Orthocell Ltd ( ($AU:OCC) ) just unveiled an announcement. Orthocell reported quarterly revenue of $3.6 million for the...

9h ago

OCC

Orthocell’s Remplir shows strong outcomes in complex prostate cancer surgeries

Orthocell Ltd ( ($AU:OCC) ) has shared an announcement. Orthocell has reported excellent early functional outcomes from an...

9d ago

OCC

Orthocell Sets November Date for Hybrid 2026 AGM and Moves to Digital Meeting Materials

The latest announcement is out from Orthocell Ltd ( ($AU:OCC) ). Orthocell Ltd has scheduled its 2026 Annual...

20d ago

OCC

Orthocell Seeks Deloitte as Auditor to Support Global Growth

Orthocell Ltd ( ($AU:OCC) ) has shared an announcement. Orthocell Ltd has proposed the appointment of Deloitte Touche...

20d ago

OCC

Orthocell Makes First Remplir Sales in Thai Nerve Repair Market

Orthocell Ltd ( ($AU:OCC) ) has shared an update. Orthocell has recorded its first commercial sales of Remplir...

1M ago

OCC

Orthocell issues new shares after option exercise, boosting tradable stock

Orthocell Ltd ( ($AU:OCC) ) just unveiled an announcement. Regenerative medicine developer Orthocell Ltd has strengthened its capital...

1M ago

OCC

Orthocell Seeks ASX Quotation for Additional Ordinary Shares

Orthocell Ltd ( ($AU:OCC) ) has shared an announcement. Orthocell Ltd has applied for quotation of 61,750 new...

1M ago

OCC

Orthocell Files 2026 Corporate Governance Appendix with ASX

Orthocell Ltd ( ($AU:OCC) ) has shared an update. Orthocell Limited has lodged its Appendix 4G with the...

2M ago

OCC

Orthocell posts full-year 2026 results and details progress in regenerative medicine portfolio

Orthocell Ltd ( ($AU:OCC) ) has provided an update. Orthocell Limited, a Perth-based regenerative medicine specialist, develops collagen-based...

2M ago

OCC

OCC FAQ

What was Orthocell Ltd’s price range in the past 12 months?

Orthocell Ltd lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.

What is Orthocell Ltd’s market cap?

Orthocell Ltd’s market cap is AU$177.06M.

When is Orthocell Ltd’s upcoming earnings report date?

Orthocell Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 120 days.

How were Orthocell Ltd’s earnings last quarter?

Orthocell Ltd released its earnings results on Aug 28, 2026. The company reported -AU$0.032 earnings per share for the quarter, missing the consensus estimate of AU$0 by -AU$0.032.

Is Orthocell Ltd overvalued?

According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Orthocell Ltd pay dividends?

Orthocell Ltd does not currently pay dividends.

What is Orthocell Ltd’s EPS estimate?

Orthocell Ltd’s EPS estimate is 0.

How many shares outstanding does Orthocell Ltd have?

Orthocell Ltd has 272,393,700 shares outstanding.

What happened to Orthocell Ltd’s price movement after its last earnings report?

Orthocell Ltd reported an EPS of -AU$0.032 in its last earnings report, missing expectations of AU$0. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Orthocell Ltd?

Currently, no hedge funds are holding shares in AU:OCC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Orthocell Ltd Stock Smart Score

Underperform

Fundamentals

Return on Equity

-36.83%

Trailing 12-Months

Asset Growth

55.54%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Orthocell Ltd

Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.

Orthocell Ltd (OCC) Earnings & Revenues

Historic Earnings Reports

OCC Stock 12 Month Forecast

Average Price Target

AU$1.13

▲(44.87% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$1.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$1.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.765,0.7930769230769231,0.8211538461538461,0.8492307692307692,0.8773076923076923,0.9053846153846153,0.9334615384615385,0.9615384615384615,0.9896153846153846,1.0176923076923077,1.0457692307692308,1.0738461538461537,1.1019230769230768,{"y":1.13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.765,0.7930769230769231,0.8211538461538461,0.8492307692307692,0.8773076923076923,0.9053846153846153,0.9334615384615385,0.9615384615384615,0.9896153846153846,1.0176923076923077,1.0457692307692308,1.0738461538461537,1.1019230769230768,{"y":1.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.765,0.7930769230769231,0.8211538461538461,0.8492307692307692,0.8773076923076923,0.9053846153846153,0.9334615384615385,0.9615384615384615,0.9896153846153846,1.0176923076923077,1.0457692307692308,1.0738461538461537,1.1019230769230768,{"y":1.13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.44,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.915,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.765,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >